Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In
NORTHBROOK, Ill., June 5, 2013
NORTHBROOK, Ill., June 5, 2013 /PRNewswire/ --Astellas Pharma US, Inc.
("Astellas"), a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503),
announced today that the company has entered into a distribution agreement
with Tecnofarma International Ltd. to distribute enzalutamide (XTANDI^® in the
U.S.) in Latin America, excluding Brazil, upon regulatory approvals in the
various countries. Financial terms of the agreements were not disclosed.
"We are pleased to initiate a distribution arrangement for enzalutamide with
Tecnofarma, which represents an important milestone to further expand our
oncology business in Latin America," said Martin Mercer, Vice President of
Latin America. "Tecnofarma, with whom Astellas already has a relationship
through our Mycamine® distribution agreement in Latin America, has a strong
Latin American sales and marketing oncology organization, which is why they
are an ideal partner to help build the Astellas oncology pipeline with
Jorge Ramos, CEO Latin America for Tecnofarma: "We want to thank Astellas for
trusting us with the distribution rights of this important product. It is an
extremely valuable new option for patients in this region."
Enzalutamide (XTANDI® in the U.S.) is an oral, once-daily androgen receptor
inhibitor. XTANDI was approved by the U.S. Food and Drug Administration on
August 31, 2012 for the treatment of metastatic castration resistant prostate
cancer for patients who have previously received docetaxel (chemotherapy). On
May 30, 2013, Health Canada approved XTANDI (enzalutamide) capsules for the
treatment of patients with metastatic castration-resistant prostate cancer in
the setting of medical or surgical castration who have received docetaxel
therapy. Marketing applications for XTANDI have also been submitted in Japan,
Europe, Switzerland, South Korea and Brazil.
Important Safety Information for XTANDI
Contraindications- XTANDI can cause fetal harm when administered to a
pregnant woman based on its mechanism of action. XTANDI is not indicated for
use in women. XTANDI is contraindicated in women who are or may become
Warnings and Precautions- In the randomized clinical trial, seizure occurred
in 0.9% of patients on XTANDI. No patients on the placebo arm experienced
seizure. Patients experiencing a seizure were permanently discontinued from
therapy. All seizures resolved. Patients with a history of seizure, taking
medications known to decrease the seizure threshold, or with other risk
factors for seizure were excluded from the clinical trial. Because of the risk
of seizure associated with XTANDI use, patients should be advised of the risk
of engaging in any activity where sudden loss of consciousness could cause
serious harm to themselves or others.
Adverse Reactions- The most common adverse drug reactions (≥ 5%) reported in
patients receiving XTANDI in the randomized clinical trial were
asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral
edema, musculoskeletal pain, headache, upper respiratory infection, muscular
weakness, dizziness, insomnia, lower respiratory infection, spinal cord
compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and
hypertension. Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1%
Grade 3-4) and in 6% on placebo (no Grade 3-4). Grade 1-4 elevations in
bilirubin occurred in 3% of XTANDI patients and 2% on placebo. One percent of
XTANDI patients compared to 0.3% on placebo died from infections or sepsis.
Falls or injuries related to falls occurred in 4.6% of XTANDI patients vs 1.3%
on placebo. Falls were not associated with loss of consciousness or seizure.
Fall-related injuries were more severe in XTANDI patients and included
non-pathologic fractures, joint injuries, and hematomas. Grade 1 or 2
hallucinations occurred in 1.6% of XTANDI patients and 0.3% on placebo, with
the majority on opioid-containing medications at the time of the event.
Drug Interactions-Effect of Other Drugs on XTANDI: Administration of strong
CYP2C8 inhibitors can increase the plasma exposure to XTANDI.
Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if
possible. If coadministration of XTANDI cannot be avoided, reduce the dose of
XTANDI. Co-administration of XTANDI with strong or moderate CYP3A4 and CYP2C8
inducers can alter the plasma exposure of XTANDI and should be avoided if
possible. Effect of XTANDI on Other Drugs: XTANDI is a strong CYP3A4 inducer
and a moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4, CYP2C9 and
CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the
plasma exposures of these drugs. If XTANDI is co-administered with warfarin
(CYP2C9 substrate), conduct additional INR monitoring.
For Full Prescribing Information, please visit www.XtandiHCP.com.
Astellas Pharma US, Inc. ("Astellas"), located in Northbrook, Illinois, is an
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical
company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products. For more
information on Astellas, please visit our website at www.astellas.us.
Tecnofarma, headquartered in Montevideo, Uruguay, is a principal supplier of
pharmaceutical products to the Latin American market. Tecnofarma provides
leading pharmaceutical products and technologies in a variety of therapeutic
categories. Tecnofarma's field sales force of approximately 2000
representatives calls on physicians and other health care professionals
throughout the region.
SOURCE Astellas Pharma US, Inc.
Contact: Jenny M. Kite, Astellas, +1-224-205-5405
Press spacebar to pause and continue. Press esc to stop.